Organization · Venture Capital
Pharma Connect Capital
Pharma Connect Capital is an early-stage life sciences investment fund based in Groningen, Netherlands, focusing on drug development, delivery technologies, biomarkers, and diagnostics. The fund is currently closed for new investments and is concentrating on maturing its existing portfolio.
Overview
What Pharma Connect Capital does
What Pharma Connect Capital is
Pharma Connect Capital is an early-stage life sciences investment fund based in Groningen, Netherlands, focusing on drug development, delivery technologies, biomarkers, and diagnostics. The fund is currently closed for new investments and is concentrating on maturing its existing portfolio.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find Pharma Connect Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Pharma Connect Capital as a funder
Investment thesis
PCC was designed to close the financing gap in early pharmaceutical innovation as large pharma delegated more development risk outward. The fund backs very early drug development, delivery, biomarker, and diagnostic projects, with a strong regional link to Northern Netherlands academic and life-science infrastructure.
Focus narrative
Pharma Connect Capital specializes in very early-stage investments in the life sciences sector, particularly in drug development and delivery technologies, biomarkers, and diagnostics. The fund emphasizes supporting academic and innovative pharmaceutical initiatives within the Northern Netherlands.
Value beyond capital
Pharma Connect Capital provides strategic support to its portfolio companies by leveraging its connections within the academic and life sciences infrastructure of the Northern Netherlands. The fund aids in development planning aligned with regulatory and quality standards before investment assessment.
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- EuropeNorth America
Availability
- Currently deploying
- No
Portfolio and track record
Portfolio context
Bioprex — A portfolio company focused on innovative pharmaceutical solutions. Glycanscan — Engaged in life sciences and diagnostics. Griphingo Pharmaceuticals — Developing innovative inhalation therapy for COPD patients. MimeCure — Active in the life sciences sector. Sabiad — Lead investor in a January 2024 seed round. Salz Biosciences — Listed as a portfolio company on PCC's official page.
Common questions
What to know about Pharma Connect Capital
Upseed classifies Pharma Connect Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.